133 related articles for article (PubMed ID: 38733406)
1. Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study.
Ikoma T; Matsumoto T; Boku S; Motoki Y; Kinoshita H; Kosaka H; Kaibori M; Inoue K; Sekimoto M; Fujisawa T; Iwai H; Naganuma M; Tanizaki H; Hisamatsu Y; Okada H; Kurata T
Cancer Immunol Immunother; 2024 May; 73(7):126. PubMed ID: 38733406
[TBL] [Abstract][Full Text] [Related]
2. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
3. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
4. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
6. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer.
Sengul Samanci N; Cikman DI; Oruc K; Bedir S; Çelik E; Degerli E; Derin S; Demirelli FH; Özgüroğlu M
Tumori; 2021 Aug; 107(4):304-310. PubMed ID: 32935638
[TBL] [Abstract][Full Text] [Related]
10. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
11. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
12. Metabolic disease and adverse events from immune checkpoint inhibitors.
Leiter A; Carroll E; De Alwis S; Brooks D; Shimol JB; Eisenberg E; Wisnivesky JP; Galsky MD; Gallagher EJ
Eur J Endocrinol; 2021 Jun; 184(6):857-865. PubMed ID: 34552304
[TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
14. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
Baldini C; Martin Romano P; Voisin AL; Danlos FX; Champiat S; Laghouati S; Kfoury M; Vincent H; Postel-Vinay S; Varga A; Vuagnat P; Ribrag V; Mezquita L; Besse B; Hollebecque A; Lambotte O; Michot JM; Soria JC; Massard C; Marabelle A
Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106
[TBL] [Abstract][Full Text] [Related]
15. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Fujimoto A; Toyokawa G; Koutake Y; Kimura S; Kawamata Y; Fukuishi K; Yamazaki K; Takeo S
Thorac Cancer; 2021 Aug; 12(15):2198-2204. PubMed ID: 34173724
[TBL] [Abstract][Full Text] [Related]
16. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer.
Johns AC; Yang M; Wei L; Grogan M; Spakowicz D; Patel SH; Li M; Husain M; Kendra KL; Otterson GA; Rosko AE; Andersen BL; Carbone DP; Owen DH; Presley CJ
Oncologist; 2023 Aug; 28(8):e625-e632. PubMed ID: 37085156
[TBL] [Abstract][Full Text] [Related]
19. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T; Kramer R; Forschner A; Leiter U; Meier F; Reinhardt L; Dücker P; Ertl C; Tomsitz D; Tietze JK; Gutzmer R; Dabrowski E; Zimmer L; Gesierich A; Zierold S; French LE; Eigentler T; Amaral T; Heinzerling L
Eur J Cancer; 2024 May; 203():114028. PubMed ID: 38652976
[TBL] [Abstract][Full Text] [Related]
20. Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhou J; Du Z; Fu J; Yi X
Front Immunol; 2023; 14():1117447. PubMed ID: 36960068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
